Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Polymer-free sirolimus-eluting stent use in Europe and Asia: Ethnic differences in demographics and clinical outcomes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
      Drug-Eluting Stents*; Coronary Artery Disease/*therapy ; Ethnicity/*statistics & numerical data ; Immunosuppressive Agents/*therapeutic use ; Myocardial Infarction/*prevention & control ; Percutaneous Coronary Intervention/*methods ; Sirolimus/*therapeutic use; Aged ; Europe/epidemiology ; Female ; Follow-Up Studies ; Humans ; Incidence ; Malaysia/epidemiology ; Male ; Mediterranean Region/epidemiology ; Middle Aged ; Myocardial Infarction/epidemiology ; Polymers ; Prognosis ; Prospective Studies ; Republic of Korea/epidemiology
    • نبذة مختصرة :
      Background: The objective of this study was to assess regional and ethnic differences in an unselected patient population treated with polymer-free sirolimus-eluting stents (PF-SES) in Asia and Europe.
      Methods: Two all-comers observational studies based on the same protocol (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were combined for data analysis to assure sufficient statistical power. The primary endpoint was the accumulated target lesion revascularization (TLR) rate at 9-12 months.
      Results: Of the total population of 7243 patients, 44.0% (3186) were recruited in the Mediterranean region and 32.0% (2317) in central Europe. The most prominent Asian region was South Korea (17.6%, 1274) followed by Malaysia (5.7%, 413). Major cardiovascular risk factors varied significantly across regions. The overall rates for accumulated TLR and MACE were low with 2.2% (140/6374) and 4.4% (279/6374), respectively. In ACS patients, there were no differences in terms of MACE, TLR, MI and accumulated mortality between the investigated regions. Moreover, dual antiplatelet therapy (DAPT) regimens were substantially longer in Asian countries even in patients with stable coronary artery disease as compared to those in Europe.
      Conclusions: PF-SES angioplasty is associated with low clinical event rates in all regions. Further reductions in clinical event rates seem to be associated with longer DAPT regimens.
      Competing Interests: All centers received a remuneration for each fully documented study patient. We report the following conflicts of interest: FK (lecturing fees B.Braun, Astra Zeneca), VK (consulting Medtronic, Abbott Vascular, Terumo) and MW/LW (full time employment at Medical Scientific Affairs, B.Braun Melsungen AG). All other authors have no other conflict of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
    • References:
      Catheter Cardiovasc Interv. 2018 Jun;91(7):1221-1228. (PMID: 28944613)
      Circ Cardiovasc Interv. 2019 Apr;12(4):e006918. (PMID: 30998393)
      Obes Rev. 2018 Nov;19(11):1525-1543. (PMID: 30261552)
      Circulation. 2007 May 1;115(17):2344-51. (PMID: 17470709)
      Eur Heart J. 2018 Jan 14;39(3):213-260. (PMID: 28886622)
      J Am Coll Cardiol. 2012 Oct 30;60(18):1733-8. (PMID: 23040575)
      Catheter Cardiovasc Interv. 2018 Nov 15;92(6):1097-1103. (PMID: 29513378)
      Am J Cardiol. 2019 Nov 15;124(10):1518-1527. (PMID: 31547997)
      Coron Artery Dis. 2012 Jun;23(4):271-7. (PMID: 22473083)
      Catheter Cardiovasc Interv. 2016 Sep;88(3):358-66. (PMID: 26650913)
      Circ Cardiovasc Interv. 2016 Jul;9(7):. (PMID: 27412869)
      Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719826335. (PMID: 30803407)
      PLoS One. 2015 Sep 14;10(9):e0136415. (PMID: 26368504)
      Indian Heart J. 2012 Sep-Oct;64(5):453-61. (PMID: 23102382)
      PLoS One. 2015 May 29;10(5):e0128252. (PMID: 26023784)
      Am J Cardiol. 2019 Jul 15;124(2):195-204. (PMID: 31103132)
      Eur Heart J. 2014 Oct 1;35(37):2541-619. (PMID: 25173339)
      Curr Vasc Pharmacol. 2018;16(5):459-476. (PMID: 29345591)
      Circulation. 2011 Jun 14;123(23):2736-47. (PMID: 21670242)
      JACC Cardiovasc Interv. 2017 Feb 13;10(3):247-254. (PMID: 28109872)
      Crit Rev Clin Lab Sci. 2015 Feb;52(1):28-44. (PMID: 25397345)
      Open Heart. 2017 Jun 6;4(2):e000592. (PMID: 28761678)
      J Geriatr Cardiol. 2016 Oct;13(10):830-835. (PMID: 27928224)
    • Molecular Sequence:
      ClinicalTrials.gov NCT02629575; NCT02905214
    • الرقم المعرف:
      0 (Immunosuppressive Agents)
      0 (Polymers)
      W36ZG6FT64 (Sirolimus)
    • الموضوع:
      Date Created: 20200114 Date Completed: 20200407 Latest Revision: 20211204
    • الموضوع:
      20221213
    • الرقم المعرف:
      PMC6957170
    • الرقم المعرف:
      10.1371/journal.pone.0226606
    • الرقم المعرف:
      31929543